Background {#Sec1}
==========

Ovarian cancer is the most lethal cause of all gynecological malignancies \[[@CR1]\]. Due to lack of specific symptoms, the majority of patients (60%) are diagnosed at advanced stages and the five-year survival rate is about 30% \[[@CR2], [@CR3]\]. Nowadays cytoreducitve surgery combined with chemotherapy has been accepted as a standard treatment of this disease, where platinum-based agents such as cisplatin and carboplatin are considered to be the essential components of most chemotherapy regimens \[[@CR4]--[@CR6]\]. Initial response rate to such first-line chemotherapy is as high as 65--80%. However, about half of these patients eventually develop platinum resistance, leading to an unfavorable prognosis \[[@CR2]\]. Presently, platinum-resistance is a major obstacle in the treatment of ovarian cancer.

Although a plenty of genes and pathways have been investigated for platinum resistance in ovarian cancer, mechanisms of drug resistance are still not fully understood. Most researchers examined only a small part of genes, meanwhile the majority of them focused on specific subtypes of ovarian cancer. As platinum resistance seems to be regulated by sophisticate molecular networks, we try to systematically assess reported genes with text mining and other bioinformatics methods, quantitatively describe their relationships and make prediction of potential regulatory molecules and pathways in this study.

Methods {#Sec2}
=======

The methods for data preparation and gene identification have been described previously \[[@CR7]\]. Briefly, *Ovarian cancer AND (cisplatin OR carboplatin)* were used as retrieval statement on Pubmed and 6160 literatures were listed (up to July 24th, 2017). All abstracts were collected from PubMed retrieval system. Genes and proteins were identified with ABNER (V1.5) \[[@CR8], [@CR9]\] and were verified based on Entrez Gene Database. To cover the description of cisplatin and carboplatin, words and shorthands such as *"platinum", "platin", "cisplatin", "DDP", "carboplatin"* and *"CBP"* were selected*.* Similarly, both *"resistance"* and *"resistant"* were identified. Only the genes that co-appeared with these two groups of words in the same sentence will be treated. If a gene appeared several times in one sentence, it would be counted once. Word frequency analysis was performed with Microsoft Excel 2010. Gene ontology analysis was carried with FunRich (V3.0) software \[[@CR10]\] and *p*-value were corrected with Bonferroni method.

Protein-protein interaction (PPI) network analysis was performed using Cytoscape (V3.4.0). Plugins such as BisoGenet \[[@CR11]\] and CytoNCA \[[@CR12]\] were used to generate network, while interaction information from MINT \[[@CR13]\], BIND \[[@CR14], [@CR15]\], BioGrid \[[@CR16]\], DIP \[[@CR17]\], IntAct \[[@CR18]\] and HPRD \[[@CR19]\] were used for analysis. All interactions were based on experiments. Hierarchical cluster analysis was performed between genes and cancer subtypes (*"serous", "mucinous", "endometrioid", "clear cell cancer"* or *"OCCC"*) using HemI (V1.0) \[[@CR20]\] with maximum distance similarity metric. Data were normalized for each subtype in advance.

Results {#Sec3}
=======

Platinum-resistance related genes in ovarian cancer {#Sec4}
---------------------------------------------------

According to the criterion of frequency analysis, 473 genes were identified within 6160 abstracts and top genes among them (count≥15) were listed in Table [1](#Tab1){ref-type="table"}. *TP53* were mentioned more than 100 times, while *ABCB1, AKT1*, *ERCC1* and other genes were also widely studied in the past years. Table 1The top platinum-resistance related genes based on text miningGeneDescriptionCount*TP53*tumor protein p53108*ABCB1*ATP binding cassette subfamily B member 164*AKT1*AKT serine/threonine kinase 159*ERCC1*ERCC excision repair 1, endonuclease non-catalytic subunit40*BCL2*BCL2, apoptosis regulator28*EGFR*epidermal growth factor receptor27*BRCA1*BRCA1, DNA repair associated26*PIK3CA*phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha25*MAPK1*mitogen-activated protein kinase 124*ABCC1*ATP binding cassette subfamily C member 122*IL6*interleukin 620*NFKB1*nuclear factor kappa B subunit 120*STAT3*signal transducer and activator of transcription 319*MTOR*mechanistic target of rapamycin kinase18*PARP1*poly (ADP-ribose) polymerase 117*TNFSF10*TNF superfamily member 1017*BRCA2*BRCA2, DNA repair associated15*HDAC1*histone deacetylase 115*TNF*tumor necrosis factor15Only the genes that co-appeared with drug name (such as "cisplatin") and phenomenons (such as "resistance") in the same sentence will & be treated

Gene ontology analysis {#Sec5}
----------------------

To explore the functions of these genes, gene ontology (GO) analysis was carried out. Significant biological processes that may involve (corrected *p* \< 0.05) in platinum resistance were shown in Table [2](#Tab2){ref-type="table"}. Apoptosis were highlighted as the most significant process, while signal transduction, cell communication, cell cycle, anti-apoptosis, and nucleobase & nucleic acid metabolism were also included. Table 2Significant biological process (GO analysis) for platinum resistance in ovarian cancerBiological ProcessNumber of GenesCorrected *P*-ValueApoptosis316.64 × 10^− 13^Signal transduction1545.19 × 10^−08^Cell communication1439.82 × 10^−07^Regulation of cell cycle80.012Anti-apoptosis60.020Regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism990.024All 473 identified genes were treated as input. *P* values were corrected with Bonferroni method

PPI network analysis {#Sec6}
--------------------

To find out important molecules in platinum resistance mechanism, PPI network was generated with Cytoscape (V3.4.0) software and its plugins. The interactions were illustrated in Fig. [1](#Fig1){ref-type="fig"} and the most popular nodes with their degrees (the number of interactions) were listed in Table [3](#Tab3){ref-type="table"}. TP53 has the highest degree than other proteins, which implies the critical function of it in platinum resistance regulation. In addition, HSP90AA1 (degree = 41), ESR1 (degree = 40), AKT1 (degree = 39), BRCA1 (degree = 35) and other proteins were also predicted as remarkable hubs among the signaling network. Fig. 1The PPI network of platinum-resistance related genes. Self-loops and isolated nodes were deleted. All interactions were based on experiments. Network was generated just among input nodes rather than their neighbours. Molecules with count less than 3 were excluded before PPI analysisTable 3The top nodes (degree\> 20) in platinum-resistance related PPI networkNodeDescriptionDegreeTP53tumor protein p5356HSP90AA1heat shock protein 90 alpha family class A member 141ESR1estrogen receptor 140AKT1AKT serine/threonine kinase 139BRCA1BRCA1, DNA repair associated35EGFRepidermal growth factor receptor34CTNNB1catenin beta 131CASP3caspase 330HDAC1histone deacetylase 128MAPK1mitogen-activated protein kinase 126STAT3signal transducer and activator of transcription 326MAPK8mitogen-activated protein kinase 825SP1Sp1 transcription factor24GSK3Bglycogen synthase kinase 3 beta23CDKN1Acyclin dependent kinase inhibitor 1A23PARP1poly (ADP-ribose) polymerase 122BCL2BCL2, apoptosis regulator21CASP8caspase 821All edges are treated as undirected. The degree of each node is calculated with CytoNCA, a plugin for Cytoscape

Cluster analysis for subtypes {#Sec7}
-----------------------------

Based on histopathology, ovarian cancer can be mainly classified into four subtypes: serous, mucinous, endometrioid and ovarian cancer of clear cell (OCCC) \[[@CR21]\]. Each major histological type has characteristic morphological features and biological behaviors \[[@CR22]\], and the incidence of platinum resistance differs from the others. For example, mucinous ovarian cancer has been reported to have a much lower sensitivity and higher resistance rate compared with serous ovarian cancer \[[@CR23], [@CR24]\].

To investigate the specific regulatory molecules for each subtype, genes co-appearing with "*serous*", "*mucinous*", "*endometrioid*" and "*clear cell*" (or *OCCC*) were collected respectively, then cluster analysis were performed. As shown in Fig. [2](#Fig2){ref-type="fig"}, each subtype has its distinctive combination for platinum-resistance molecules. Some genes such as *TP53* are commonly focused in most subtypes. By comparison, *BCL2* and *AKT1* were frequently mentioned in endometrioid cancer while *ERBB2* and *AGR3* were repeatedly mentioned in mucinous cancer. Such genes may be regarded as specific regulators or markers for each subtype. Fig. 2Hierarchical cluster analysis for genes among subtypes of ovarian cancer. Cluster analysis was performed based on maximum-linkage, using similarity metric of maximum distance. Each subtype was normalized respectively before cluster analysis

Discussion {#Sec8}
==========

Cisplatin and carboplatin exert antitumor effects by binding to DNA and forming cross-links, thus disrupts DNA structure and finally results in cell apoptosis \[[@CR25]\]. Dysregulation in that process may cause platinum resistance. Among all possible regulatory mechanisms, the most important ones include the followings \[[@CR26]\]: (1) Suppressed uptake or enhanced efflux can reduce cytosol accumulation of platinum. (2) Drug detoxification mechanism can protect cells from bioactive platinum aquo-complexes. (3) DNA repair can be activated and enhanced to restore DNA damages. (4) Changes in signaling pathways make cells evade fate of apoptosis. These mechanisms and pathways interact with each other, making platinum-resistance regulation very complex. It should be noted that cisplatin and carboplatin share similar molecular structures and are cross-resistant in most cases. In contrast, oxaliplatin are not cross-resistant with them, which may be explained by the lipophilic cyclohexane residue \[[@CR27]\]. So oxaliplatin resistance is not discussed in this study.

According to Table [1](#Tab1){ref-type="table"}, most of the top genes can be classified into the four categories mentioned above, and apoptosis is the most significant process in Table [2](#Tab2){ref-type="table"}. The tumor-supressor P53 is a central hub for the activation of intrinsic apoptotic pathway \[[@CR28]\]. It can trigger cell death via the expression of apoptotic genes and by inhibiting the expression of anti-apoptotic genes \[[@CR29]\]. *BCL2* can inhibit cell death induced by cytotoxic factors such as chemotherapeutic drugs and enhance cell resistance \[[@CR30], [@CR31]\].

For platinum accumulation, both *ABCB1* (MDR1) and *ABCC1* (MRP1) belong to ATP binding cassette (ABC) transport protein family, which works as ATP-dependent drug efflux pump and is responsible for decreased platinum accumulation \[[@CR32], [@CR33]\]. Among all the identified molecules, *ABCG2* (count = 13) and *ABCC2* (count = 10) have similar functions though not listed in Table [1](#Tab1){ref-type="table"}. Another example for transporter protein is *SLC31A1* \[[@CR34]\] (also known as *CTR1*), a member of copper transporter family, which plays a significant role in platinum uptake \[[@CR35]\].

For DNA damage/repair, *ERCC1* (ERCC excision repair 1) is a critical member of nucleotide excision repair induced by platinum \[[@CR36]\]. Meanwhile, *BRCA1* \[[@CR37]\] and *BRCA2* \[[@CR38]\] exert their functions in double-stranded breaks repair of DNA. *PARP1* can recognize DNA lesions and modifies various nuclear proteins which are involved in the regulation of DNA repair \[[@CR39]\].

Both *GSTA1* (count = 12) and *GSTP1* (count = 9) belong to the top 10% of all identified genes though not listed in Table [1](#Tab1){ref-type="table"}. The expression products of them are members of cellular detoxification system, which can add glutathione to platinum, block the formation of Pt-DNA and reduce cytotoxicity of platinum \[[@CR40], [@CR41]\].

Besides, some popular genes such as *AKT1*, *EGFR*, *PIK3CA*, *MAPK1*, *NFKB1* and *MTOR*, are difficult to be classified. All of them have multiple functions in physiological and pathological processes and are regarded as key nodes in platinum-resistance signaling network (as shown in Table [3](#Tab3){ref-type="table"}). Their effects toward platinum resistance have been extensively explored, together with their various targets or regulators \[[@CR42]--[@CR45]\].

There are specific genomic alterations and gene-expression patterns for different subtypes of ovarian cancer. According to previous reports, *K-RAS* mutation is very common in mucinous ovarian carcinomas (75%), but the rate is generally low in clear cell carcinomas \[[@CR46], [@CR47]\]. Meanwhile, genes involved in nucleotide excision repair (such as *XPB* and *ERCC1*), were found to be preferentially expressed in ovarian clear cell carcinomas \[[@CR48], [@CR49]\]. That suggests each subtype may have specific mechanism and molecular character for platinum resistance, but there are few reports for this topic. In our study, genes were enriched according to their co-occurring subtypes and then subjected to cluster analysis. This method helps us understand the differences in regulatory mechanisms among subtypes of ovarian cancer. It is also meaningful for clinical accurate diagnosis and individualized treatment of ovarian cancer.

A potential limitation in this study is the performance of text mining. It can recognize names of genes and proteins, calculate their frequencies and judge the functions of them via co-occurrence analysis, but it cannot really "understand" literatures. However, it is still an effective method to quantitatively assess gene functions and their relationships, especially for comprehensive analysis with large input data.
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